{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DDI+%28Drug-Drug+Interaction%29&page=3",
    "query": {
      "condition": "DDI (Drug-Drug Interaction)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 71,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DDI+%28Drug-Drug+Interaction%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DDI+%28Drug-Drug+Interaction%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T05:47:30.918Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02647086",
      "title": "Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-12",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-22",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647086"
    },
    {
      "nct_id": "NCT05202145",
      "title": "Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALXN2050",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 61,
      "start_date": "2022-01-11",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05202145"
    },
    {
      "nct_id": "NCT01074073",
      "title": "Lithium Drug-Drug Interaction Study With Lurasidone HCl",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-08",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2011-09-08",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "Culver City, California",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01074073"
    },
    {
      "nct_id": "NCT06370728",
      "title": "A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Orforglipron",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2024-05-06",
      "completion_date": "2024-07-23",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06370728"
    },
    {
      "nct_id": "NCT00000772",
      "title": "A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": null,
      "completion_date": "1995-02",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000772"
    },
    {
      "nct_id": "NCT02311946",
      "title": "A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Palbociclib Alone",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib + Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2015-01",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2015-05-28",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • South Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02311946"
    },
    {
      "nct_id": "NCT04782076",
      "title": "A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loxo Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2021-03-05",
      "completion_date": "2021-05-17",
      "has_results": true,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04782076"
    },
    {
      "nct_id": "NCT02277600",
      "title": "A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "BMS-663068",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-11-05",
      "completion_date": "2015-01-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277600"
    },
    {
      "nct_id": "NCT00920296",
      "title": "DDI Study of Etravirine and GSK1265744",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-07",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-31",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920296"
    },
    {
      "nct_id": "NCT07629999",
      "title": "Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986533",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran Etexilate",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 136,
      "start_date": "2026-07-13",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-13T05:47:30.918Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07629999"
    }
  ]
}